The purpose of this study is to explore the differences in socioeconomic and demographic factors between clinical trial participants and non-participants, and to explore whether clinical trial participation influences overall clinical outcomes. This is a retrospective chart review that will collect sociodemographic and economic factors of all multiple myeloma patients and identify differences between clinical trial participants and non-participants, as well as analyze whether clinical trial participation influenced clinical outcomes of these patients.
The purpose of this study is to test a potential new medicine, NNC6019-0001, for people who have heart disease due to transthyretin (TTR) amyloidosis. The study will compare the new medicine at two dose levels (10 mg/kg and 60 mg/kg) to placebo on change in a 6-minute walk test and N-terminal pro-brain natriuretic peptide (NT-proBNP) test from baseline to week 52, or occurrence of death or cardiovascular hospitalization, in participants with hereditary transthyretin amyloidosis or wild-type transthyretin amyloid cardiomyopathy.
The purpose of this study is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor. The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias or incident heart failure.
The purpose of this study is to compare the standard of care therapy (VRd + Rd therapy) and CAR-T therapy (VRd + CAR-T) for newly diagnosed multiple myeloma patients who do not plan to receive hematopoietic stem cell transplant as initial therapy.
The purpose of this study is to collect real-world data on the safety and efficacy of the MANTA vascular closure device using ultrasound guidance in stopping blood flow/close catheter access sites at the end of large-bore interventional cardiology procedures compared to using pre-procedural depth locator measurements.
The purpose of this study is to determine if the use of colchicine, a drug that reduces inflammation, can lower the risk of having a stroke or heart attack from blood clots compared to placebo, and improve recovery in people with a recent brain bleed.
The purpose of this study is to determine whether a 6-month course of oral micronised purified flavonoid fraction (MPFF), compared with placebo, improves the symptoms and signs of post-thrombotic syndrome (PTS) and quality of life at six months follow-up.
The purpose of this study is to collect information to determine if some ablation strategies work better than others for treating atrial fibrillation.
The purpose of this study is to support an indication of inclisiran for the reduction of cardiovascular risk in participants with established atherosclerotic cardiovascular disease who have elevated low-density lipoprotein cholesterol levels despite being on a background of well-tolerated dose of a high-intensity statin therapy.
The purpose of this study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), who have previously been treated with at least 2 tyrosine kinase inhibitors. Additionally, this study will investigate the usage of two different dosing regimes of asciminib, 80mg daily and 40mg twice daily.
The purpose of this study is to compare standard treatment against a newly approved medication for patients presenting to the emergency department with a heart condition called atrial fibrillation. A sub-study will also look at a new consenting process in the emergency department and the experience of patients with this consent process.
The purpose of this study is to understand the ability of genetic testing to identify familial hypercholesterolemia among patients with acute cardiac event in hospital settings and to investigate the impact of genetic diagnosis on physician behaviour, medication use and decreasing cholesterol to an acceptable level.
The purpose of this study is to investigate if and how retinal blood vessels change after a spinal cord injury (SCI) and the associations of these changes with cardiovascular diseases. Using images of retinal blood vessels, we will develop a deep learning-based screening tool for autonomic dysreflexia, a cardiovascular complication unique to SCI.
The purpose of this study is to investigate whether Electrical Vestibular Stimulation (EVS) can lessen orthostatic hypotension in Parkinson’s disease patients. We aim to determine if individual precision-designed EVS stimulus can be optimized for improvements in hypotension.
The purpose of this study it to examine the safety and efficacy of gene-modified T cell therapy in patients who have previously received the treatment.
The purpose of the study is to find the best technique and tools for gaining access to left and right heart arteries using x-rays that show blood flow, in patients who are having a specific Medtronic heart valve inserted.
The purpose of the study is to determine the safety and effectiveness of the drug TQJ230 to lower Lipoprotein(a) to reduce cardiovascular events in patients with a history of heart disease.
The purpose of the study is to provide data demonstrating the safety and effectiveness of the PulseSelect™ PFA System for the treatment of atrial fibrillation.
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
The purpose of this study is to determine if the drug empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
The purpose of the study is to evaluate the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.